Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

ing of BioMarin's clinical trials of GALNS, Firdapse, PEG-PAL, BMN-673 , BMN-701 and other product candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, Firdapse, and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme, Kuvan, and Firdapse; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, particularly with respect to GALNS, Firdapse, PEG-PAL, BMN 673 and BMN 701; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme, Kuvan and Firdapse; actual sales of Aldurazyme, Naglazyme Kuvan and Firdapse; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2010 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pha
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to ... Composition of Material, Application (Healthcare, Homeland security, Industrial ... (Personal Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) ... 2013 - 2020", published by MarketsandMarkets, the Scintillator Market is ... from 2014 to 2020, and reach $479.16 Million ...
(Date:7/11/2014)... 11, 2014  Australian drug delivery company, Phosphagenics Limited ... raised A$19.3 million via a placement of A$16.3 million ... the U.S., Asia and ... share purchase plan (SPP) to be offered to existing ... in two tranches. "This capital raising positions ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Nov. 1, 2010 The National Quality Forum ... of its eight member councils.   ... to improving the quality of American healthcare by ... endorsing national consensus standards for measuring and publicly ...
... Octapharma AG , one of ... and Octapharma USA today announced that patients ... a multi-center study that is researching the use of ... human cell line (Human-cl rhFVIII). Researchers are investigating Human-cl ...
Cached Medicine Technology:National Quality Forum Members Elect New Council Leaders 2Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line 2Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line 3
(Date:7/13/2014)... 2014 Athletes with a certain genetic ... concussions, according to research presented today at the American ... Meeting. The research marks the first of its kind ... known physical events that occur after a head injury. ... allele in the (GT)n genotype were four times more ...
(Date:7/13/2014)... Rico (PRWEB) July 13, 2014 ... of Famer, Chris Mullin, will be the featured guest ... July 26th in Puerto Rico. Attendees will learn ... will participate in two exhibition basketball games and perform ... ultimate supplier of health- and energy-boosting supplements , ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Epidemiologists forecast ... in the 6MM, from 8,062 diagnosed incident cases in ... an Annual Growth Rate (AGR) of 4.35%, during the ... highest number of diagnosed incident cases of aGVHD in ... will have the lowest number of diagnosed incident cases ...
(Date:7/13/2014)... According to the Kidney Disease Solution book ... step guide on what to do to eliminate the root ... writes in its review that readers can easily learn what ... their kidney health. Vkool also informs in its Kidney Disease ... damaged kidney functions naturally. The book consists of a collection ...
(Date:7/13/2014)... Beverly Hills, California (PRWEB) July 13, 2014 ... Champion Danny Musico has formed a promotional partnership with ... revolutionary plant based Omega-3 EPA supplement . The ... Musico is a celebrity fitness trainer , actor, ... As Hollywood’s go-to trainer for A-List celebrities, he has ...
Breaking Medicine News(10 mins):Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... 2 Hess Corporation will present two $50,000 checks -- one ... other to Children,s Hospital Boston,s Trauma Program -- as part of ... opening day. Aric Morrison, a Hess Retail regional director, will present ... promised to donate $500 for every home run hit during a ...
... in ongoing program to prevent adverse health events ... Thirty-one Minnesota hospitals recently were named winners of the ... awards honor hospitals, efforts to prevent four types of ... invasive procedures and foreign objects retained during labor and ...
... CHICAGO, Oct. 2 Beginning October 1st, The Peninsula Chicago ... Cancer Awareness Month and several cancer research and education organizations. ... by breast cancer in some way and this is why ... said Maria Zec, general manager of The Peninsula Chicago. "In ...
... devastation of the 1918-1919 influenza pandemic is well known, but ... death toll: the misuse of aspirin. Appearing in the November ... the article sounds a cautionary note as present day concerns ... dosing levels used to treat patients during the 1918-1919 pandemic ...
... more improves outcomes, study shows , FRIDAY, Oct. 2 ... bypass surgery can be used to reverse morbid obesity ... U.S. researchers say. , Their study included 61 teens ... Hospital Medical Center. One year after surgery, overall body ...
... lead to better treatments, researchers say, , FRIDAY, Oct. ... stomach cancers could lead to more effective treatments and ... say. , For a study published online Oct. 1 ... stomach tumors from people in Australia, Singapore and Great ...
Cached Medicine News:Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 3Health News:Thirty-one Minnesota Hospitals Win Patient Safety Awards 2Health News:The Peninsula Chicago Gives Back During Breast Cancer Awareness Month 2Health News:Delaying Weight-Loss Surgery May Leave Teens at Risk 2Health News:New Classification Proposed for Stomach Cancers 2
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
... Macula Plus® 5.5 is ... of the optic nerve ... it with your binocular ... choroidal neovascular membranes, macular ...
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
The iQ200 Automated Urinalysis System (iQ System) is a user-friendly, bench top, fully automated system that performs complete urinalyses on unspun specimens; simply load, press START and walk away....
Medicine Products: